Pathophysiological Influences on Pharmacokinetics and Pharmacodynamics, 2nd Edition
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Pharmacokinetics and Pharmacodynamics".
Deadline for manuscript submissions: 31 October 2026 | Viewed by 1010
Editors
Interests: placental pharmacokinetic; pregnancy; high-risk pregnancy; infection in obstetrics
Special Issues, Collections and Topics in MDPI journals
Interests: clinical pharmacokinetics; pharmacometrics; PBPK; in vitro drug metabolism
Special Issues, Collections and Topics in MDPI journals
Interests: clinical pharmacology; model-informed precision dosing; pharmacokinetics; drug-disease interactions
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Pharmaceutics is excited to announce a Special Issue on “Pathophysiological Influences on Pharmacokinetics and Pharmacodynamics, 2nd Edition”. This Special Issue aims to explore the latest advancements in PK and PD research across a diverse range of pathophysiological conditions.
Understanding how both diseases and physiological changes alter drug disposition is essential for tailoring pharmacological treatments to individual patients. Such insights are crucial to ensuring that therapies are both safe and effective. Disease states—such as infections, inflammatory states, and acute and chronic diseases—can significantly impact drug absorption, distribution, metabolism, and excretion, leading to variability in drug response that may result in adverse effects or therapeutic failure.
A key objective of clinical pharmacology is to promote individualized pharmacotherapy by identifying the factors that contribute to variability in drug response, with a particular focus on PK and PD. Many conditions, including bacterial, viral, fungal, and protozoal infections, chronic diseases like type 2 diabetes, neoplasms, autoimmune disorders, and physiological states such as pregnancy, are known to influence drug disposition. However, there remains a notable gap in the literature regarding the characterization of drug-metabolizing enzymes and transporters in both disease states and physiological conditions, particularly by in vivo activity markers.
This Special Issue seeks to address these gaps by highlighting recent progress in understanding the impact of both pathophysiological and physiological factors on drug kinetics and dynamics. Potential topics of interest include, but are not limited to, the following:
- Characterization of drug kinetic disposition in patients with specific pathophysiological or physiological conditions;
- Comparisons of PK and/or PD between healthy individuals and those with diseases or altered physiological states;
- Exploration of how disease states and physiological conditions can modify drug absorption, distribution, metabolism, and excretion;
- Impact of comorbidities and physiological changes on pharmacotherapy outcomes;
- Optimization of drug therapy in patients with altered physiological states, including pregnancy;
- Advances in PBPK modeling that account for pathophysiological and physiological influences.
We invite researchers from academia, government agencies, and industry to submit their work to this Special Issue. Each submission will undergo rigorous peer review and be edited by leading experts in the field to ensure the highest standards of quality and relevance. If you are interested in further discussion, please feel free to contact the Guest Editors.
Dr. Geraldo Duarte
Dr. Fernanda de Lima Moreira
Dr. Jhohann Richard de Lima Benzi
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- drug–disease interactions
- pharmacokinetics
- pharmacodynamics
- pharmacotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
